Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GELATIN CAPSULE PELLICLE FORMATION DOES NOT AFFECT IN VIVO RELEASE FDA

Executive Summary

GELATIN CAPSULE PELLICLE FORMATION DOES NOT AFFECT IN VIVO RELEASE FDA and industry have tentatively concluded. The conclusion that currently marketed gelcap drug products do not pose immediate concern with regard to dissolution failures resulted from a March 1 meeting between industry and FDA on in vitro dissolution testing of soft and hard gelatin capsules. FDA's Office of Generic Drugs called the meeting "to discuss recent findings in the field concerning multiple hard and soft gelatin capsuled products failing dissolution testing due to pellicle formation." While most of the meeting participants concluded that the formation of a skin-like film on the gelatin capsules of certain drug products does not reflect a serious in vivo problem at the current time, FDA said it plans to form a working group "to address science and regulatory issues associated with these dosage forms." FDA added that "further effort on the topic will occur at [the Center for Drug Evaluation and Research] under the direction of the newly formed Chemistry, Manufacturing and Controls Coordination Committee (CMCCC)." FDA said a joint agency and industry open workshop on gelcaps may be held in the future. FDA's field findings had received a preliminary evaluation by a task force convened by the CMCCC headed by OGD Director Roger Williams and Office of Drug Evaluation I Assistant Director for Chemistry Charles Kumkumian. The task force had recommended further evaluation of the problem to determine whether the in vitro dissolution data is an indicator of in vivo bioavailability for the gelatin capsule products. FDA and industry plan to continue to look at the available data to determine whether pellicle formation has any affect on the in vivo performance of drugs. They also will study whether an in vitro dissolution test may be developed to better indicate how the gelap products dissolve in patients' stomachs. Meeting attendees included representatives from the U.S. Pharmacopoeia, the Generic Pharmaceutical Industry Association, the National Association of Pharmaceutical Manufacturers, the National Pharmaceutical Alliance and the Pharmaceutical Manufacturers Association. Representatives from gelatin capsule manufacturers Warner-Lambert, Lilly and R.P. Scherer participated in the meeting.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel